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NURR1 in Psoriasis and Modulation following TNF-a
Inhibition
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Oliver FitzGerald2, Brian Kirby2,3 and Evelyn P. Murphy1
The orphan nuclear receptor NURR1 belongs to the NR4A subfamily of transcription factors which are emerging
as important mediators of cytokine and growth factor signaling. The transcriptional function of these ligand-
independent and constitutively active receptors is controlled at the level of expression and nuclear localization.
This study examines the expression of NURR1 in psoriasis and biological effects on this receptor following
inhibition of tumor necrosis factor-a (TNF-a) signaling. We report increased expression of NURR1 mRNA and
protein in involved psoriasis skin compared with uninvolved and normal skin, which correlates significantly
(P¼ 0.0055) with clinical measures of the psoriasis area and severity index. Enhanced NURR1 expression
localizes to both nucleus and cytoplasm of cells of involved epidermis, blood vessels, and inflammatory
infiltrates, in contrast to predominant cytoplasmic distribution in uninvolved and normal skin. Endogenous
NURR1 levels are rapidly and selectively increased in response to proinflammatory agonists and growth factors
in normal dermal endothelial cells. Following TNF-a inhibition with infliximab or etanercept, NURR1 mRNA and
protein levels in involved skin are significantly decreased and cytoplasmic distribution is restored. These
findings establish the aberrant expression and distribution of NURR1 in psoriasis and suggest that clinical
benefits of TNF-a inhibition may be mediated through altered NURR1 activity.
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INTRODUCTION
Psoriasis is a chronic, inflammatory autoimmune dermatosis
that affects 2% of the world population, and is associated
with significant morbidity and negative impact on quality of
life (Sampogna et al., 2004). It is characterized by accumula-
tion of erythematous, scaly plaques with characteristic
histological changes of epidermal hyperplasia, inflammatory
cell infiltrate, and increased vascularity. Approximately 15%
of patients develop inflammatory seronegative arthritis,
psoriatic arthritis (PsA) (Krueger and Bowcock, 2005).
The etiology of psoriasis is multifactorial and linked with
multiple genetic and environmental factors. There is evi-
dence for both acquired and innate immune dysregulation,
with a complex interplay between abnormally activated
T-helper lymphocytes, keratinocytes, and the dermal vascular
endothelium (Kirby and Griffiths, 2002). Increased produc-
tion and release of cytokines and growth factors by activated
T lymphocytes triggers basal stem cell keratinocyte prolifera-
tion, abnormal terminal differentiation, and resistance to
apoptotic signals (Bata-Csorgo et al., 1995; Wrone-Smith
et al., 1997). These inflammatory mediators also support
vascular changes and promote angiogenesis, which is a
prominent and early event in psoriasis (Brooks et al., 1994;
Paleolog et al., 1998; Leong et al., 2005).
Therapeutic studies of tumor necrosis factor-a (TNF-a)
inhibition confirm that this cytokine occupies a prominent
place in the hierarchy of signaling molecules and plays a key
role in amplifying inflammatory processes associated with
psoriasis and PsA (Griffiths et al., 2006). Selective TNF-a
inhibitors, including etanercept and infliximab, demonstrate
a high degree of clinical benefit in both skin and joint disease
(Gottlieb et al., 2005). TNF-a inhibition significantly reduces
cellular infiltration and vessel number with normalization of
keratinocyte differentiation in the skin (Lizzul et al., 2005;
Markham et al., 2006b).
Putative roles for primary keratinocyte defects in psoriasis
include the corneodesmosin gene (Capon et al., 2004) and
abnormal expression of amphiregulin (Chung et al., 2005)
and telomerase (Jurisic et al., 2007) by keratinocytes.
Neurogenic pathways may also be important in psoriasis.
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Several reports document absence of skin and joint disease in
areas of sensory denervation and various neuropeptides
including corticotropin-releasing hormone (CRH) are in-
creased in psoriasis involved skin (Veale et al., 1993; O’Kane
et al., 2006; Saraceno et al., 2006). Psychological stress
significantly affects disease expression and treatment re-
sponses (Fortune et al., 2003), with some patients demon-
strating abnormal hypothalamic–pituitary–adrenal axis
responses to acute psychological stress. The role of this
‘‘brain–skin axis’’ in psoriasis is incompletely understood.
The NR4A subgroup of orphan nuclear receptors (NURR1,
NUR77, and NOR-1) belong to the superfamily of ligand-
inducible transcription factors, which include receptors for
steroid hormones, retinoids, and vitamin D (Mangelsdorf
et al., 1995). Transcripts for the NR4A subgroup are
constitutively expressed in the central nervous system and
play an important role in the coordinate neuroendocrine
regulation of the activity of the hypothalamic–pituitary–adre-
nal axis, including negative feedback inhibition by gluco-
corticoids (Murphy and Conneely, 1997). In the pituitary,
NURR1 and NUR77 mediate the transcriptional effects of
CRH to regulate the gene expression of POMC, the precursor
of ACTH. Of note, NURR1 also contributes to the pro-
inflammatory actions of peripheral CRH signaling in human
inflammatory joint disease including rheumatoid and PsA
(Murphy et al., 2001).
As ligand-independent nuclear receptors, the activity of
NR4A transcription factors is tightly controlled at the level of
protein expression and nuclear accumulation (Maxwell and
Muscat, 2006), as well as post-translational modification
including phosphorylation (Wingate and Arthur, 2006).
NR4A receptors can interact with other transcription factors
including the retinoic acid receptor and co-regulatory
proteins to modulate gene expression (Zetterstrom et al.,
1996; Wansa and Muscat, 2005; Maxwell and Muscat,
2006). Unlike most nuclear receptors, however, these
proteins are products of immediate early genes whose
expression can be differentially induced in response to a
variety of signals (Pei et al., 2005; Wansa and Muscat, 2005).
Members of the NR4A subfamily are both necessary and
sufficient to regulate vascular endothelial growth factor
(VEGF)-mediated angiogenesis in vitro and in vivo (Liu
et al., 2003; Zeng et al., 2006). The NR4A receptors
contribute to cellular transformation and promote tumor
growth by enhancing cell proliferation and mediating TNF-a-
dependent cell survival pathways (Suzuki et al., 2003; Li
et al., 2006).
In chronic inflammatory diseases including arthritis and
atherosclerosis, the NR4A receptors are emerging as key
regulators of cytokine and growth factor action (McEvoy
et al., 2002b; Bonta et al., 2006). In human synoviocyte cells,
transcriptional activation of the NURR1 gene by TNF-a
involves NF-kB signaling pathways (McEvoy et al., 2002b).
Elevated levels of NURR1 in synoviocyte cells promote
increased expression of IL-8, amphiregulin, and Kit ligand,
which may act to promote cell recruitment, proliferation, and
survival in the inflamed joint (Davies et al., 2005).
Significantly, recent in vivo studies establish NURR1 as a
molecular target of methotrexate action in the treatment of
PsA (Ralph et al., 2005).
We report for the first time increased NURR1 expression
and nuclear localization in psoriasis skin, and evidence
implicating NURR1 in abnormal keratinocyte proliferation
in psoriasis. Our in vitro studies support a role for TNF-a
in modulating NURR1 levels and cellular localization in
psoriasis, while the pathological importance of this nuclear
receptor was confirmed by establishing that TNF-a inhibition
can alter the transcriptional regulatory capacity of NURR1
in vivo.
RESULTS
NURR1 expression is increased in psoriatic involved and
uninvolved skin compared with normal skin
The expression and localization of NURR1 protein in
psoriatic involved and uninvolved skin and normal controls
was determined using immunohistochemical analysis. In all
involved psoriasis skin samples, abundant staining was seen
in the epidermis, dermal blood vessels, and inflammatory
infiltrate in and around vessels. Uninvolved and normal skin
showed a similar distribution of expression; however NURR1
immunostaining was consistently weaker (Figure 1a–c).
Higher-power views demonstrated that NURR1 expression
localized to both nuclear and cytoplasmic compartments in
involved skin in contrast to a predominantly cytoplasmic
pattern of expression in uninvolved and normal skin. In
clinically involved skin, nuclear staining was particularly
marked in basal epidermal keratinocytes and scattered
collections of suprabasal keratinocytes (Figure 1a and b),
papillary loop vessels (Figure 1b), and dermal blood vessels
(Figure 1c). In contrast, vascular staining in uninvolved and
normal skin was mainly cytoplasmic (Figure 1c). The
specificity of NURR1 staining was confirmed by absence of
staining found on serial tissue sections treated with NURR1
antibody that had been preincubated with an excess of
specific antigen (blocking peptide) (Figure 1d). Immunostain-
ing with isotype-matched nonimmune IgG also yielded
negative findings in all skin tissue examined (results not
shown).
NURR1 mRNA expression was assessed in involved
(n¼12), uninvolved (n¼ 10) and normal skin samples
(n¼4) using reverse transcriptase PCR (RT–PCR). Consistent
with the results of the immunohistochemical analysis,
NURR1 mRNA levels were higher and more widely
distributed in involved and uninvolved psoriasis skin
compared with normal skin. While the difference in NURR1
mRNA levels between involved and uninvolved skin (Figure
1e) was not statistically significant (P¼ 0.1537, Student’s
unpaired t-test), NURR1 mRNA was significantly elevated in
involved skin compared with normal controls. (P¼0.0165,
Student’s unpaired t-test). NURR1 mRNA levels in clinically
involved skin correlated significantly with psoriasis area and
severity index (PASI) (Spearman r¼ 0.5961, P¼0.0055).
Nuclear coexpression of NURR1 and Ki 67 in involved skin
The expression of NURR1 was further examined by dual
labeling of involved (n¼5), uninvolved (n¼5), and normal
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(n¼3) skin, using double labeling indirect immunofluore-
scence techniques. Two-color immunofluorescence staining
for NURR1 and Ki 67 was performed. Ki 67 antigen is a cell-
cycle-related nuclear protein, expressed by proliferating cells
in all phases of the active cell cycle (G1, S, G2, and M
phases) and is absent in resting (G0) cells. It is commonly
used as a marker of proliferating keratinocytes in psoriasis,
where it is expressed in both basal and suprabasal epidermal
layers in contrast to normal skin, where expression is
restricted to the basal layer. In all samples analyzed, dual
staining demonstrated that the majority of Ki 67-positive cells
in the basal and suprabasal layers of involved epidermis also
expressed NURR1 in a nuclear distribution. This was in
marked contrast to uninvolved and normal epidermis, where
nuclear colocalization was almost absent (Figure 2), con-
firming that the abnormal proliferation of keratinocytes in
psoriasis is associated with nuclear accumulation of NURR1
protein.
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Figure 1. NURR1 protein and mRNA levels are elevated in psoriasis skin
compared with normal controls. Tissue sections from involved and
uninvolved skin of patients with psoriasis and normal controls were stained
with rabbit anti-NURR1 primary antibody and hematoxylin counterstain.
Positive cells stain light/mid brown (cytoplasmic NURR1) and dark brown/
black (nuclear NURR1). Negative cells stain blue. (a) NURR1 expression in
psoriasis involved and uninvolved skin, and normal control skin. (b) High-
power views of boxed areas. (c) High-power view of dermal blood vessels in
psoriatic involved and uninvolved skin, and normal control. (d) Negative
control: serial sections stained with NURR1 rabbit anti-NURR1 primary
antibody following preabsorption with specific NURR1 blocking peptide.
BVL, blood vessel lumen. Bars¼ (a) 100m, (b, c) 25 m. (e) Total RNA was
isolated from biopsies of involved and uninvolved psoriasis skin and normal
controls and NURR1 mRNA levels assessed using RT-PCR. NURR1 mRNA
levels were normalized to GAPDH. Bars indicate the group means.
(*P¼0.0165, mean7SEM, Student’s unpaired t-test.)
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Figure 2. Coexpression of NURR1 and Ki 67 in the epidermis of involved
psoriasis skin. Tissue sections from involved and uninvolved skin of patients
with psoriasis and normal controls were subjected to double labeling indirect
immunofluorescence using polyclonal rabbit anti-NURR1 and monoclonal
mouse anti-Ki67 primary antibodies detected by Cy3 anti biotin and FITC
anti-mouse fluorescent secondary antibodies. Red: NURR1, green: Ki 67,
yellow: colocalization of NURR1 and Ki 67, blue: DAPI (nuclear
counterstain). Low-power views: epidermis and dermis; Bar¼ 100m.
High-power views: basal/suprabasal epidermis; Bar¼10 m.
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Pro-inflammatory mediators, including TNF-a, promote
increased NURR1 expression and nuclear localization in
primary human dermal microvascular endothelium
To elucidate the molecular signals leading to aberrant
NURR1 expression in psoriatic skin, we examined the ability
of inflammatory cytokines and growth factors to regulate
endogenous NURR1 levels in normal primary dermal
microvascular endothelial cells (HMVECs). The effects of
proinflammatory agonists on NURR1 mRNA were assessed
using Northern blot analysis. Consistent with NURR1
immunostaining in the vasculature in normal skin, basal
NURR1 mRNA and protein levels in dermal HMVECs were
low (Figure 3a–c). Characteristic of immediate early response
genes, induction of NURR1 transcription by proinflammatory
agonists exhibited a rapid turnover, with maximal NURR1
mRNA levels peaking at 1 hour (Figure 3a and b) and
returning to basal levels within 3 hours (results not shown).
Effects on NURR1 mRNA levels following treatment of
dermal HMVECs with TNF-a (3.7-fold), IL-1b (3.7-fold), or
prostaglandin E2 (PGE2) (2.4-fold) were comparable and co-
administration of these mediators augmented the effects on
NURR1 transcription additively (10.2-fold) (Figure 3a) The
magnitude of this additive response was comparable to the
effects of forskolin (FOR), an established activator of protein
kinase pathways shown previously to induce NURR1
expression in many different cell types. Stimulation of dermal
HMVECs with the growth factors basic fibroblast growth
factor (bFGF), platelet derived growth factor (PDGF), or
transforming growth factor-b resulted in the selective induc-
tion of NURR1 mRNA by bFGF (4.6-fold). Interestingly,
despite lack of induction by transforming growth factor-b or
PDGF, synergistic effects on NURR1 mRNA levels were
observed when all three growth factors were added
simultaneously (18.3-fold) (Figure 3b). Immunofluorescence
studies of NURR1 expression in HMVECs confirmed that
treatment with cytokines, PGE2, or forskolin also induced a
rapid and marked increase in endogenous NURR1 protein
(Figure 3c). Importantly, NURR1 immunostaining in treated
cells was enhanced and predominantly nuclear compared
with the cytoplasmic localization in untreated cells. Immuno-
fluorescence analysis with nonimmune IgG showed an
absence of staining (Figure 3c).
Anti-TNF-a treatment reduces nuclear NURR1 expression in
psoriatic keratinocytes and blood vessels in vivo
The demonstration that psoriatic skin showed increased
levels of NURR1 compared to normal skin and the ability
of proinflammatory mediators, including TNF-a, to modulate
NURR1 expression and localization in dermal cells in vitro
(Figures 1 and 3), prompted us to explore the effects of anti-
TNF-a treatment on NURR1 expression in vivo. NURR1
expression and cellular distribution were assessed using
immunohistochemical analysis of involved psoriasis skin at
baseline and at week 12 of etanercept treatment (Figure 4,
n¼5). All patients had active psoriasis at baseline assess-
ment, with a mean PASI¼3.88. At baseline biopsy, all
patient skin (involved and uninvolved) demonstrated histo-
logical features of tissue inflammation. Microscopic analysis
of involved psoriatic skin confirmed increased epidermal
thickness, dermal inflammatory cell infiltrate, and extensive
dermal vascularization (Figure 4a). Consistent with previous
reports on the immunomodulatory effects of etanercept
treatment in psoriatic skin disease (Gottlieb et al., 2005), all
patient tissue demonstrated significant reduction in epidermal
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Figure 3. Rapid effects on NURR1 expression and nuclear distribution in human primary dermal endothelial cells (HMVECs) by inflammatory stimuli
and growth factors. (a, b) Human primary dermal endothelial cells were treated for 1 hour with vehicle (Ctrl), forskolin (FOR, 25 mM), PGE2 (1 mM), IL-1b
(10 ng/ml), TNF-a (10 ng/ml), transforming growth factor-b (10 nM), bFGF (10 nM), and PDGF (10 nM), as indicated. Total RNA (10 mg/lane) was analyzed by
Northern blotting using 32P-labeled cDNA probes. GAPDH was used as a loading control. (c) Human primary dermal endothelial cells were treated for
1 hour with vehicle (Ctrl), forskolin (FOR, 25mM), PGE2 (1 mM), IL-1b (10 ng/ml) or TNF-a (10 ng/ml). The cells were then permeated and stained using an
anti-NURR1 immune serum or isotype control matched IgG. Bar¼ 25 m.
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thickness, inflammatory cell infiltrate and vascularization
(Figure 4b).
Before treatment, NURR1 immunostaining was extensive
in all tissue samples (n¼ 5), with abundant nuclear staining
observed in the epidermis, dermal blood vessels, and
inflammatory infiltrate of involved skin (Figure 4a and b).
Treatment effects on involved skin included overall reduction
in the intensity of NURR1 staining, with a marked decrease in
nuclear expression in basal keratinocytes (Figure 4c and d),
papillary loop vessels (Figure 4d), dermal vessel endothelium
(Figure 4e), and inflammatory cells in and around dermal
vessels (Figure 4f). Importantly, most of the NURR1 staining
that remained during treatment was predominantly cytoplas-
mic and comparable to the levels and localization of NURR1
seen in uninvolved or normal skin (Figure 1).
To verify that the consistent changes in NURR1 protein
levels following etanercept treatment (Figure 4a–f) correlated
with changes in NURR1 transcription, total RNA was
extracted from baseline involved skin (n¼5), baseline
uninvolved skin (n¼5), and involved skin at week 12 post
etanercept (n¼ 5), and assessed using RT-PCR. Consistent
with the results of our previous analysis (Figure 1e), NURR1
mRNA levels were elevated in involved skin samples and
showed a wide distribution (Figure 5g). Following treatment,
NURR1 mRNA levels in involved skin were reduced and
statistical analysis was performed to compare baseline
involved skin with baseline uninvolved and post-treatment
skin. NURR1 mRNA levels were significantly (P¼0.043)
reduced post treatment compared with baseline involved skin
(Figure 5g). Importantly, etanercept treatment effectively
reduced NURR1 mRNA to equivalent levels of NURR1
expressed in uninvolved skin.
Nuclear NURR1 expression is reduced following treatment with
anti-TNF-a agents and PUVA
We next assessed the in vivo effects on NURR1 expression
using infliximab treatment, an alternative anti-TNF-a agent,
and compared the effects of this biologic to etanercept
treatment and also to a well established and efficacious
nonbiologic treatment, psoralen-ultraviolet A (PUVA). In-
volved and uninvolved psoriasis skin at baseline and involved
skin at week 12 of infliximab (n¼ 6) or etanercept (n¼ 5), or
week 20 of PUVA (n¼2) treatment, was subjected to
immunohistochemical analysis. The majority of patients
assessed had a significant clinical response to treatment.
There was a broad range of values for PASI pretreatment
(mean¼ 8.2, range 1.5–21.9), with mean PASI post-treatment
of 3.6 (range 0–7.8).
Comparable changes in NURR1 expression and cellular
distribution were seen following etanercept, infliximab, and
PUVA treatments (Figure 5a). We subsequently performed
quantitative analysis of NURR1 nuclear staining in all patient
tissue before and following each treatment. Since etaner-
cept’s effects on NURR1 expression included reduction and a
clearing of nuclear localization in discrete areas of the
epidermis, dermis, and blood vessels (Figure 5), we
performed a separate and detailed quantification for each of
these areas following different treatments (Figure 5d). The
percentage of cells positive for NURR1 nuclear staining in
clinically involved skin was significantly reduced
(Po0.0001) post treatment to levels comparable to those in
uninvolved and normal skin (Figure 5d). Equivalent changes
were seen in all tissue areas assessed, including suprabasal
and basal epidermis, papillary loop vessels, dermal vessels,
dermal fibroblasts, and perivascular inflammatory cells
(Figure 5d). Of note, most NURR1 immunostaining that
remained during treatment was predominantly cytoplasmic
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Figure 4. Etanercept treatment reduces NURR1 expression and alters
NURR1 cellular distribution in vivo. Biopsies were taken from the involved
skin of patients with psoriasis at baseline and after 12 weeks of etanercept
treatment. Tissue sections were treated with rabbit anti-NURR1 primary
antibody and a hematoxylin counterstain. Positive cells stain light/mid brown
(cytoplasmic NURR1) and dark brown/black (nuclear NURR1). Negative cells
stain blue. (a) Cytoplasmic and nuclear NURR1 distribution at different levels
of the epidermis and dermis in pretreatment involved skin. (b) Changes in
NURR1 expression levels and distribution following treatment. (c–f) High
power views of suprabasal epidermis (c), basal dermis and dermal papillary
loop vessels (d), dermal vessels and dermal perivascular inflammatory
infiltrate (e–f), together with corresponding areas post treatment. (g) Changes
in NURR1 mRNA expression in psoriasis skin following treatment with
etanercept. Total RNA was isolated from biopsies of clinically involved and
uninvolved skin at baseline and involved skin post etanercept therapy at 12
weeks. NURR1 mRNA levels were assessed using semi-quantitative RT-PCR
and normalized to GAPDH. The graph shows NURR1 mRNA levels in
baseline involved (n¼5), baseline uninvolved (n¼ 5), and post-treatment skin
(n¼5). (Mean7SEM, Student’s unpaired t-test, *Po0.05.) Bars¼ (a, b) 50 m,
(c–f) 25 m.
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and was comparable to the NURR1 staining observed in
uninvolved and normal skin tissue (Figure 1).
DISCUSSION
In this study, we have, for the first time, characterized the
expression of the orphan nuclear receptor NURR1 in
psoriasis, demonstrating elevated levels in involved skin
compared to uninvolved and normal skin. In contrast to
clinically involved skin, our analysis of uninvolved and
normal skin revealed reduced NURR1 expression at both
gene and protein level, with primarily cytoplasmic protein
distribution observed in epidermis and dermal vessels. In
particular, the basal epidermal layer of normal skin showed
almost complete absence of nuclear expression, suggesting
nontranscriptional functions for NURR1. Further in vivo
studies demonstrated modulation of NURR1 expression and
cellular location following successful treatment of psoriasis
with anti-TNF-a agents. Since NURR1 is a known down-
stream target of TNF-a (McEvoy et al., 2002b), this nuclear
receptor may represent a novel therapeutic target with
perhaps less side effects than current anti-TNF-a agents.
The NR4A group of transcription factors have recently
been shown to play key roles in regulating cell growth and
transformation, apoptosis, angiogenesis, and inflammation
(Li et al., 2006; Maxwell and Muscat, 2006). These receptors
are also implicated in diabetes and atherosclerosis via roles in
lipid and glucose metabolism (Bonta et al., 2006; Pei et al.,
2006b). Thus, characterization of their role in psoriasis may
contribute to a further understanding of the pathogenesis of
psoriasis as well as recently discovered associations between
psoriasis and other systemic inflammatory diseases such as
coronary vascular disease and diabetes (Neimann et al.,
2006; Sommer et al., 2006).
Our observation of diffuse epidermal NURR1 expression,
with enhanced nuclear localization in basal and focal
suprabasal layers areas that colocalized with Ki 67, suggests
that in addition to being transcriptionally active in these cells,
NURR1 may also be involved in the abnormal keratinocyte
proliferation, which is a key feature in psoriasis. This could
occur via upregulation of amphiregulin expression, an
autocrine growth factor for keratinocytes, which induces
epidermal hyperplasia, which is increased in psoriasis
lesional skin, overexpressed in a mouse model of psoriasis,
and associated with synovitis (Cook et al., 2004). Amphir-
egulin has recently been described as a target gene
modulated by NURR1 transcriptional activity in human
synoviocyte cells (Davies et al., 2005). Additional mechan-
isms might involve anti-apoptosis effects, since Nur77,
another NR4A group member, has both pro- and antiapopto-
tic functions depending on nuclear or cytoplasmic localiza-
tion (Li et al., 2006). So far, only antiapoptotic properties
have been demonstrated for NURR1 (Li et al., 2006).
Interestingly, differential nuclear and cytoplasmic distribution
in psoriasis has recently been shown for another antiapop-
tosis protein, survivin, whose nuclear translocation is thought
to be an important regulatory mechanism controlling cell
proliferation (Markham et al., 2006a). A further role for
NURR1 in cell transformation is supported by the fact that
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Figure 5. Effects of different treatment modalities on NURR1 expression and
cellular distribution in psoriasis involved skin. (a–c) Immunohistochemical
analysis of NURR1 protein expression in clinically involved skin before and
after treatment with infliximab (n¼6), etanercept (n¼5), or PUVA (n¼2).
Biopsies were taken from the involved skin of patients with psoriasis at
baseline and at 12 weeks post infliximab or etanercept, or 20 weeks post
PUVA treatment. Sections were stained with anti-NURR1 primary antibody
and hematoxylin counterstain and representative sections are shown. Positive
cells stain light/mid brown (cytoplasmic NURR1) and dark brown/black
(nuclear NURR1). Negative cells stain blue. (d) Quantification of NURR1
nuclear staining in different areas of the epidermis and dermis using a
validated quantitative six-point score, where 0¼o 1% positive cells and
5X75% positive cells. (Scores performed for clinically involved (n¼ 13) and
uninvolved (n¼10) skin at baseline, involved skin post treatment (n¼ 13),
and normal controls (n¼ 4).) (Mean7SEM, ***Po0.0001, **Po0.005
Student’s unpaired t-test.) Dermal interstitial cells: fibroblasts and
inflammatory cells around vessels. Bar¼ (a–c) 100 m.
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NURR1 upregulation is a feature of tumorigenicity in several
cancer cell lines (Ke et al., 2004; Li et al., 2006) and PGE2-
mediated protection from apoptosis in colorectal cancer
depends on NURR1 signaling via CREB (Holla et al., 2006).
NURR1 expression in dermal vessels of involved skin may
reflect involvement in angiogenesis, a key early feature of
psoriasis that involves upregulation of VEGF and its receptors,
endothelial cell proliferation and survival (Markham et al.,
2006b). Transcriptional regulation of NURR1 gene by VEGF
has been reported recently (Liu et al., 2003), while NURR1
can regulate neurophilin, a VEGF receptor expressed in the
central nervous system (Hermanson et al., 2006). Vascular
NURR1 expression in psoriasis might also play a role in
survival of newly formed vessels via antiapoptotic mechani-
sms. The role of NURR1 expression by cells of the
inflammatory infiltrate in and around dermal vessels (Figure 4)
is less clear, although a similar finding has been reported in
inflamed PsA synovium, where NURR1 expressing cells
include macrophage cells of the synovial lining layer and
subsynovial regions (Murphy et al., 2001; McEvoy et al.,
2002a).
Certain potential downstream targets of NURR1 are also
known to be overexpressed in psoriasis skin, notably at
similar locations to those of NURR1. These include IL-8, a
central cytokine involved in neutrophil trafficking and
expressed in basal and suprabasal keratinocytes (Nickoloff
et al., 1991; Ackermann et al., 1999; Jiang et al., 2001);
VEGF, expressed by keratinocytes and dermal vessels and
involved in angiogenesis in psoriasis (Markham et al., 2006b)
and NF-kB (Johansen et al., 2005).
The in vitro effects of proinflammatory cytokines and
growth factors on endogenous NURR1 expression in primary
dermal endothelial cells are consistent with the pattern of
NURR1 expression in psoriasis skin. Basal levels of NURR1
mRNA and protein were low in unstimulated endothelial
cells, whereas stimulation with mediators including TNF-a
and IL-1b resulted in elevated mRNA and protein levels with
predominant nuclear localization. Activation of NURR1
transcription by TNF-a and IL-1b in human synoviocyte cells
has previously been shown to involve the p50 and p65
subunits of NF-kB, which is known to regulate the expression
of proinflammatory and prosurvival genes (McEvoy et al.,
2002b; Pei et al., 2006a).
PGE2 is a major cylooxygenase-2 product that has been
shown to mediate VEGF-induced angiogenesis in primary
endothelial cells (Hernandez et al., 2001). In this study PGE2
induces NURR1 expression and nuclear localization in
primary endothelial cells, suggesting a possible role for
NURR1 in modulating prosurvival and proliferative path-
ways, which could be relevant in the maintenance of newly
formed vessels in psoriasis. PGE2 signals through increased
concentrations of intracellular cAMP and altered protein
kinase A activity (McEvoy et al., 2004). The development of
novel inhibitors with cellular potency and high protein kinase
A selectivity act as effective inhibitors of VEGF-induced
endothelial cell growth (Kuo et al., 2005). Activation of
cAMP/PKA/CREB signaling plays a central role in the
regulation of cell proliferation associated with synovitis
(Wakisaka et al., 1998), and negative modulators of cAMP/
PKA/CREB signaling have been shown to inhibit IL-6 and IL-8
production and cell hyperproliferation (Takeba et al., 2000).
The rapid induction of NURR1 in endothelial cells following
treatment with growth factors including PDGF, may be
significant in the context of a recent study describing a role
for NR4A receptors in the regulation of PDGF-induced
proliferation of vascular smooth muscle (Nomiyama et al.,
2006).
The in vivo effects of treatment with TNF-a inhibitors
include a reduction in NURR1 levels and reveal that NURR1
cellular localization is restored to that observed in unin-
volved or normal skin. This suggests that the marked clinical
effects of anti-TNF-a agents in skin may occur via their effects
on NURR1 transcriptional activity. Reductions in nuclear
NURR1 protein expression by anti-TNF-a medications were
similar to changes in skin treated with PUVA, which is also
known to promote apoptosis of TNF-a-producing cells
(Coven et al., 1999). Our group has previously shown that
the effects of methotrexate in inflamed psoriatic synovium
include a significant (P¼0.001) reduction in NURR1 protein
levels and an absence of nuclear expression in lining layer
cells, endothelium, and inflammatory cell infiltrate (Ralph
et al., 2005). Further studies in skin incorporating earlier time
points, larger treatment cohorts, and a range of different
treatments, would determine whether changes in NURR1 are
primarily due to direct effects of a therapeutic agent on
mediators upstream of NURR1 (such as TNF-a, adenosine), or
simply secondary to clinical improvement in psoriasis.
NURR1 and other NR4A group members have an
important role in central hypothalamic–pituitary–adrenal axis
regulation including transcriptional effects on CRH, POMC,
and enzymes that control cortisol production. NURR1
expression in skin suggests similar pathways may operate
locally since the skin is both a target and source of steroid
hormones (Slominski et al., 2005) and recent reports confirm
a local cutaneous hypothalamic–pituitary–adrenal-like system
which responds to local stressors and may form part of the
increasingly recognized ‘‘brain–skin pathway’’ (Slominski
et al., 2006b). Involvement of the NR4A group in peripheral
regulation of steroidogenesis has been reported in the testis
(Hong et al., 2004) where NF-kB activation by TNF-a has
been shown to inhibit transactivation by Nur77 resulting in
suppression of genes required for steroidogenesis. Peripheral
CRH has proinflammatory actions in the skin (Slominski
et al., 2006a), is also upregulated in inflamed synovium and
CRH receptor-mediated responses have been shown to signal
through NURR1 (Murphy et al., 2001). Increased CRH
expression and colocalization of CRH receptors in the same
cells that express NURR1 in psoriasis skin (unpublished
observations) suggests that CRH, via NURR1 signaling, may
be involved in psoriasis pathogenesis.
Our work, and that of others, supports a role for NURR1 in
the regulation of pathways controlling cell proliferation,
apoptosis, and angiogenesis, key events that promote
chronic inflammation. It is however unclear whether these
transcription factors are primarily proinflammatory or
whether in situations of physiological conditions or early/
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acute inflammation, they may also have a protective role.
There is for example compelling evidence regarding the role
of NR4A receptors in both pro-resolution and protective
pathways, in the pathogenesis of atherosclerosis (Bonta et al.,
2006). This study contributes to evidence for a role for
NURR1 in promoting TNF-a-mediated mechanisms of
inflammation at local sites such as skin and joint, and may
help to explain the association of systemic inflammatory
disease such as atherosclerosis (Gelfand et al., 2006; Mallbris
et al., 2006; Neimann et al., 2006; Wakkee et al., 2007) and
metabolic syndrome (Sommer et al., 2006) with severe
psoriasis. While anti-TNF-a agents are undoubtedly effective
in treating psoriasis and PsA, modulation of NURR1 activity
may be a potential alternative downstream target in future
psoriasis therapies.
MATERIALS AND METHODS
Patients and biopsies
Patients with moderate to severe chronic plaque psoriasis (n¼ 10),
and some with both psoriasis and psoriatic arthritis (n¼ 5), were
recruited from the dermatology and rheumatology outpatients
departments at the Adelaide and Meath Hospital Dublin and the
Rheumatology department at St Vincent’s University Hospital
Dublin, respectively. Ethical approval was obtained from the local
Hospital Ethics Committee in accordance with the Declaration of
Helsinki Principles. Following informed, written consent, patients
underwent clinical assessment and skin biopsy before beginning
treatment with etanercept, infliximab, or PUVA. Etanercept
(Enbrels) was given as a twice weekly 25mg subcutaneous dose.
Infliximab (Remicades, Centocor, Malvern, PA) was given at a dose
of 3–5mg/kg at weeks 0, 2, and 6. PUVA was given twice weekly
according to standard protocols. All patients were followed up
through week 20. Clinical evaluations performed at baseline and
weeks 12, 16, and 20 included the PASI for skin and the three-
variable disease activity score for joints.
Punch biopsies (6mm) were taken from the leading edge of active
plaques and from uninvolved skin at least 5 cm from involved skin.
Biopsies were taken from the extensor surface of upper or lower
limbs. Pre- and post-treatment biopsies were taken from the same
site. Biopsies from four healthy volunteers were used as normal
controls. Each biopsy was divided into two parts for RT-PCR and
immunohistological analysis; specimens for immunohistological
analysis were immersed in Tissue Tek OCT compound (Sakura,
Zoeterwoude, The Netherlands) and snap frozen in liquid nitrogen
for storage at 801C until required.
Cell culture and stimulation
Primary dermal HMVECs were commercially sourced (BioWhittaker,
San Diego, CA) and cultured in EBM2s-MV media (BioWhittaker) as
previously described (Xu et al., 1994). Cells were grown in T25cm2
flasks for RNA analysis, or plated onto sterile eight-chambered tissue
culture treated glass slides for subsequent immunofluorescence
staining. All cells were used between 4 and 6 passages and grown to
80% confluency before stimulation. Cells were grown in serum-free
media for 24 hours then left untreated, or treated for 1 hour with
vehicle (Ctrl), forskolin (25 mM) (Sigma-Aldrich, Dorset, UK), PGE2
(1mM) (Sigma, St Louis, MO), recombinant human IL-1b (10 ng/ml)
(Calbiochem, San Diego, CA), TNF-a (10 ng/ml) (Calbiochem, San
Diego, CA), transforming growth factor-b (10 nM) (R&D Systems,
Oxfordshire, UK), bFGF (10 nM) (R&D Systems), and PDGF (10 nM)
(R&D Systems) before Northern blot analysis; or treated for 1 hour
with vehicle (Ctrl), forskolin (FOR, 25 mM Sigma-Aldrich), PGE2
(1mM) (Sigma), recombinant human IL-1b (10 ng/ml) (Calbiochem,)
and TNF-a (10 ng/ml) (Calbiochem), before immunofluorescence
analysis.
Immunohistochemistry
Cryostat serial skin sections (7 mm) were cut, mounted on 3-
aminopropyltriethoxysilane-coated glass slides, air dried overnight
at 371C then wrapped in foil and stored at 801C until required.
Sections were fixed in 1% paraformaldehyde for 20minutes.
Endogenous peroxidases were quenched before staining by treat-
ment with 0.5% H2O2 for 5minutes and nonspecific binding sites
blocked by incubation with dilute normal goat serum (Vector
Laboratories, Burlingame, CA) for 2 hours. A three-step immunoper-
oxidase staining technique was employed. Sections were stained
with a polyclonal rabbit anti-NURR1 primary antibody (Santa Cruz
Biotechnology, Heidelberg, Germany) that recognizes the amino
terminus (N20) of human and rat NURR1. The primary antibody was
diluted (1/350) in 10% normal goat serum (Vector Laboratories) and
incubated with sections overnight at 41C. Biotinylated anti-rabbit
secondary antibody was added the following day and sections
incubated with the avidin–biotin–peroxidase complex (VECTASTAIN
Elite ABC kit; Vector Laboratories). Negative controls included
sections stained with isotype-matched nonimmune IgG and primary
antibody preabsorbed with excess specific synthetic peptide (block-
ing peptide; Santa Cruz Biotechnology). Color was developed in a
solution containing diaminobenzidine tetrahydrochloride (Sigma)
and 0.5% H2O2 in phosphate-buffered saline (pH 7.6). Slides were
counterstained with hematoxylin and mounted. Microscopic analy-
sis was performed on randomly coded slides by two blinded
assessors. Where differences in scoring occurred, slides were
reviewed by both assessors and a consensus score obtained.
Randomly selected high-power fields at  400 magnification were
scored using a six-point scoring system, where 0o1% positive cells;
1, 1–10%; 2, 11–25%; 3, 26–50%; 4, 51–75%, and 5, 76–100%. A
minimum of 10 high-power fields in each section was averaged to
give a mean score. For each high-power field, a separate score for
percentage positive cells was made for suprabasal epidermis, basal
epidermis, papillary loop vessels, dermal blood vessels, and dermal
interstitial cells. Percentage cells positive for nuclear NURR1 and for
cytoplasmic NURR1 were scored separately. These scoring tech-
niques have been previously validated and reported (Youssef et al.,
1998a, b).
Immunofluorescence studies
Single labeling immunofluorescence. Primary dermal HMVEC
were grown on eight-chambered culture slides (BD Biosciences) and
maintained in serum-free endothelial growth media-2 microvascular
(EGM-2mv) media for 24 hours before stimulation with cytokines
and growth factors as described above. Following stimulation, media
was removed and cells washed with ice-cold phosphate-buffered
saline, permeated and fixed in 1% paraformaldehyde. Cells were
incubated with diluted normal goat serum (Vector Laboratories) for
2 hours then incubated with NURR1 polyclonal antibody (N-20,
200mg/ml) (Santa Cruz Biotechnology) diluted 1:10 in 10% normal
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human serum, for 90minutes. A biotinylated secondary anti-rabbit
antibody (Vector Laboratories) was added for 30minutes (1:500,
Vector Laboratories), followed by incubation with a Cy3 fluoro-
chrome-conjugated anti-biotin mAb (BN-34; 1.2mg/ml; 1:100,
Sigma). Slides were mounted in fluorescent mounting medium
(Dako, Carpinteria, CA). Isotype-matched nonimmune IgG and
primary antibody preabsorbed with its specific synthetic peptide
were used as negative controls.
Double labeling immunofluorescence. Cryosections were pre-
pared from involved, uninvolved, and normal skin as in the previous
section and sequential dual labeling for NURR1 performed using a
NURR1 polyclonal antibody (N-20, 200 mg/ml) (Santa Cruz Biotech-
nology) diluted 1:10 in 10% normal human serum, for 90minutes,
followed by incubation with a biotinylated secondary anti-rabbit
antibody (Vector Laboratories) as above. Following a second
blocking step using normal goat serum (Vector laboratories) for
1 hour, a monoclonal Ki 67 antibody (DAKO Cytoformaton,
Glostrup, Denmark) was applied for 1 hour. The primary antibodies
NURR1 and Ki 67 were detected by application of a Cy3
fluorochrome-conjugated anti-biotin mAb (BN-34; 1.2mg/ml;
1:100, Sigma) and FITC-conjugated goat anti-mouse antibody
respectively, visualized by a Carl Zeiss fluorescent microscope with
subsequent image analysis using Axiovision LE Rel 4.6 software.
Mounting techniques and negative controls were as above for single
labeling immunofluorescence.
RNA preparation and complementary DNA synthesis
Total RNA (tRNA) was isolated from psoriasis skin and normal
control skin using TRIzolTM (Invitrogen). The absorbance at 260 and
280nm was measured using a spectrophotometer to determine the
concentration and quality of RNA. Quality was also assessed by
agarose gel electrophoresis. Complementary DNA was synthesized
from 1 or 2mg of tRNA using Moloney murine leukemia virus reverse
transcriptase. PCR was performed to amplify specific gene sequences
using Platinum Taq and oligonucleotide primers for NURR1 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The sense
(50-CGA CAT TTC TGC CTT CTC C-30) and antisense (50-GGT AAA
GTG TCC AGG AAA AG-30) primer pair was used to amplify human
NURR1, yielding a 277-bp product. The sense (50-CCA CCC ATG
GCA AAT TCC ATG GCA-30) and antisense (50-TCT AGA CGG CAG
GTC AAG TCC ACC-30) primer pair was used to amplify GAPDH,
yielding a 465-bp product. Both primer pairs flanked intron
sequences. The conditions for amplification were as follows: an
initial denaturation step at 971C for 2minutes, followed by
denaturation at 971C for 30 seconds, primer annealing at 551C for
30 seconds, and extension at 721C for 30 seconds. PCR was
performed in 50-ml volumes containing 2 ml of cDNA reaction
mixture, 1.25mM of each dNTP, 100 ng of each primer, and 2mM
MgCl2. Each sample underwent a 30-cycle amplification for GAPDH
and 35 cycles for NURR1. These cycle numbers were chosen
following optimization experiments on a range of patient samples,
normal control samples, and positive control tissue, which ensured
that the reactions had not reached the plateau phase of amplification
at these cycle numbers. PCR products were electrophoresed on a
1.5% agarose gel, visualized with ethidium bromide under UV light,
and recorded both on film and as jpeg images (ImageMaster VDS,
Amersham Biosciences, Buckinghamshire, UK). The band size was
compared to a 100-bp DNA ladder. Densitometric analysis of PCR
products was performed to obtain semi-quantitative values for
NURR1 normalized to GAPDH. Using the Student’s unpaired t-test,
comparisons were made between involved and uninvolved skin at
baseline; involved and normal control skin at baseline; pre- and
post-treatment involved skin.
Northern blot analysis
Cell cultures grown in 25-cm2 tissue culture flasks were maintained
in serum-free EBM2-MV media for 24 hours before treatment as
described above. Total RNA was isolated from cultured primary
dermal HMVEC using the RNeasy minikit (Qiagen, Crawley, West
Sussex, UK) and quantified by UV absorption, then 10 mg of total
RNA was electrophoresed on a standard Northern gel and transferred
to nylon membrane (Bio-Rad, Hercules, CA). NURR1 cDNA,
spanning the amino-terminal region to avoid cross-hybridization,
and GAPDH cDNA were radiolabeled to a high specific activity
using [a-32P]dCTP, using a random primer labeling system (Promega,
Southampton, UK) (Murphy and Conneely, 1997). Blots were
exposed to film at 801C using intensifying screens, and autoradio-
graphic intensity was quantified using an imaging densitometer.
Densitometric values provided are representative of at least three
separate experiments and are expressed as fold induction over basal
levels relative to GAPDH expression.
Statistical analysis
Data analysis was preformed using InStat software (GraphPad).
Student’s unpaired t-test was used to compare differences between
groups, and Spearman’s rank correlation was used to assess
correlation of NURR1 mRNA levels with PASI.
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